Rare disease patients face a number of unique challenges and complexities of their conditions, Often, this means that their families and advocates are more engaged with the scientific and research community in comparison to some other disease and patient focus groups. By collaborating with rare disease patients, their families and various stakeholders involved on the design, positioning and subsequent enrollment of clinical trials, studies can be completed faster and more efficiently. PRA Health Sciences' Scott Schliebner (Vice President, Rare Diseases, Scientific Affairs) and Altair da Silva (Senior Manager, Patient Access and Recruitment Services) are joined by Neil Weisman (Executive Vice President and General Manager at Blue Chip Marketing) to discuss the patient voice and the importance of patient and caregiver insight.
PRA Exceeds Tough Enrollment Goals
A Phase IIb, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the safety, tolerability and efficacy of Study Drug in…
Site Commercial Solutions
Our Site Commercial Solutions are comprehensive, end-to-end commercial management solutions built directly into your trial.
Alzheimer's Disease Research 2018
PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community…